Amilcar Rivera, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: Num. 80 Calle 3 Sur, Guayama, PR 00784 Phone: 787-866-1212 Fax: 787-866-3322 |
Jesus Zayas, Pediatrics - Adolescent Medicine Medicare: Not Enrolled in Medicare Practice Location: #3 Carretera, Avenida Albizu Campos, Guayama, PR 00784 Phone: 787-864-4682 |
Dr. Aurelio Santiago Fortier, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 26 Calle Ashford N, Guayama, PR 00784 Phone: 787-864-6754 |
Dr. Jeffrey Quinones, MD, MBA Pediatrics Medicare: Not Enrolled in Medicare Practice Location: La Fuente Town Ctr, Suite 11123, Guayama, PR 00784 Phone: 787-866-1129 |
Dr. Rafael O. Rendon, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 7 Parq Interamericana, Guayama, PR 00784 Phone: 787-864-3087 |
Leroy A Perez, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: Ave Los Veteranos, Suite 1 Nieves Petit Mall, Guayama, PR 00784 Phone: 787-864-0148 |
Mr. Dalvin Olivero, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: Calle Enrique Glez #2 Esq Calimano, Guayama, PR 00784 Phone: 787-866-1449 |
Dr. Luis A Lugo, M.D. Pediatrics - Adolescent Medicine Medicare: Not Enrolled in Medicare Practice Location: 7 Calle Baldorioty E, Guayama, PR 00784 Phone: 787-864-4610 |
News Archive
Running is great exercise but not everyone feels great doing it. In hopes of boosting physical activity - and possibly creating a new mode of transportation - engineers at Stanford University are studying devices that people could strap to their legs to make running easier.
Ligand Pharmaceuticals Incorporated announced today that it has received $2 million in milestone payments from N. V. Organon, a subsidiary of Merck & Co., Inc., stemming from its research collaboration that is due to expire at the end of December.
Acera, Inc., a Massachusetts based startup focused on OEM LED lighting solutions for endoscopy and other technical applications will be launching its line of products at MEDICA, November 13-17, 2016, as part of the Mass Life Sciences presence at this prestigious medical device trade fair.
Osiris Therapeutics, Inc. announced today that the Biologics and Genetic Therapies Directorate of Health Canada has completed its initial evaluation and accepted for full review the company's New Drug Submission (NDS) of Prochymal (remestemcel-L), an adult stem cell therapy for the treatment of graft vs. host disease (GvHD). Based on a separate review of summary clinical data, Health Canada has notified Osiris that the application has been granted Priority Review, shortening the examination period from 300 to 180 days.
› Verified 9 days ago